共 50 条
- [31] Rapid symptomatic improvement with subcutaneous infliximab induction treatment for patients with moderate-to-severe Crohn's disease: first results from the DIRECT-CD studyJOURNAL OF CROHNS & COLITIS, 2024, 18 : I1682 - I1683Anjie, S.Jharap, B.Jansen, J. M.Mares, W. G.Duijvestein, M.Maljaars, J. P. W.Oldenburg, B.D'Haens, G. R. A. M.Gecse, K. B.
- [32] Changes of fecal calprotectin concentrations after adalimumab induction therapy in patients with moderate-to-severe Crohn's diseaseJOURNAL OF CROHNS & COLITIS, 2015, 9 : S362 - S362Lee, K. -M.Yang, S. -K.Kim, H. J.Kim, Y. H.Song, G. A.Im, J. P.Jang, B. I.Jung, S. -A.Jeen, Y. T.Koo, J. S.Cheon, J. H.Park, S. J.Kim, Y. J.Eun, C. S.Kim, T. -O.
- [33] Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (02) : 398 - 407Rich, P.Bourcier, M.Sofen, H.Fakharzadeh, S.Wasfi, Y.Wang, Y.Kerkmann, U.Ghislain, P. -D.Poulin, Y.
- [34] Long-Term Efficacy and Safety of Maintenance Infliximab for the Treatment of Moderate-to-Severe Pediatric Crohn's Disease: Results from the Reach StudyGASTROENTEROLOGY, 2009, 136 (05) : A671 - A672Hyams, Jeffrey S.Blank, MarionJohanns, JewelCrandall, WallaceKugathasan, SubraGriffiths, Anne M.Heuschkel, RobertMarkowitz, JamesCohen, Stanley A.Winter, Harland S.Veereman, GigiFerry, George D.Walters, Thomas D.Baldassano, Robert
- [35] Disease Characteristics Associated With Bowel Urgency in Crohn's Disease: Results From the Phase 3 VIVID-1 TrialAMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1047 - S1047D'Haens, Geert R.Sands, Bruce E.Jairath, VipulTravis, SimonChaparro, MariaPeyrin-Biroulet, LaurentChen, MinhuDubinsky, Marla C.Ferrante, MarcSchreiber, StefanMcGinnis, KimVadhariya, AishaYu, GuangleiProtic, MarijanaMoses, RichardGhosh, Subrata
- [36] Sargramostim improves quality of life as measured by the inflammatory bowel disease questionnaire in patients with moderate to severe Crohn's diseaseAMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S269 - S269Laplante, SDieckgraefe, BKorzenik, J
- [37] Correlation of endoscopic and clinical endpoints during induction therapy in patients with moderate-to-severe Crohn's disease: Analysis from CELEST studyJOURNAL OF CROHNS & COLITIS, 2018, 12 : S375 - S376Sandborn, W. J.Feagan, B.Lewis, J. D.Danese, S.Reinisch, W.Rubin, D. T.Zhou, W.Cataldi, F.Zhou, Q.Goteti, S.Lacerda, A. P.
- [38] USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIALGASTROENTEROLOGY, 2021, 160 (06) : S409 - S409Danese, SilvioVermeire, SeverineD'Haens, GeertPanes, JulianDignass, AxelMagro, FernandoNazar, MaciejLe Bars, ManuelaLahaye, MarjoleinNi, LioudmilaGaya, Daniel R.Peyrin-Biroulet, Laurent
- [39] Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn's Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE StudyGASTROENTEROLOGY, 2021, 161 (02) : E28 - E28D'Haens, Geert R.Colombel, Jean FredericBossuyt, PeterDanese, SilvioLim, AllenLindsay, JamesHisamatsu, TadakazuRan, ZhihuaRubin, David T.Neimark, EzequielHuang, BidanLiao, XiaomeiBerg, SofieDuan, W. RachelWallace, KoriSandborn, William J.
- [40] EFFICACY AND SAFETY OF OPEN-LABEL MAINTENANCE THERAPY WITH SUBCUTANEOUS RISANKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASEGASTROENTEROLOGY, 2017, 152 (05) : S1310 - S1310Feagan, Brian G.Panes, JulianFerrante, MarcKaser, ArthurD'Haens, Geert R.Sandborn, William J.Louis, EdouardNeurath, MarkusFranchimont, DenisDewit, OlivierSeidler, UrsulaKim, Kyung-JoSelinger, ChristianPadula, Steven J.Herichova, IvonaRobinson, Anne M.Wallace, KoriZhao, JunSoaita, AdinaVisvanathan, SudhaHall, DavidBocher, Wulf O.